Structural basis for therapeutic inhibition of complement C5
Jore, Matthijs M.; Johnson, Steven; Sheppard, Devon; Barber, Natalie M.; Li, Yang I.; Nunn, Miles A.; Elmlund, Hans; Lea, Susan M.. 2016 Structural basis for therapeutic inhibition of complement C5. Nature Structural & Molecular Biology, 23 (5). 378-386. 10.1038/nsmb.3196
Full text not available from this repository.Abstract/Summary
Activation of complement C5 generates the potent anaphylatoxin C5a and leads to pathogen lysis, inflammation and cell damage. The therapeutic potential of C5 inhibition has been demonstrated by eculizumab, one of the world's most expensive drugs. However, the mechanism of C5 activation by C5 convertases remains elusive, thus limiting development of therapeutics. Here we identify and characterize a new protein family of tick-derived C5 inhibitors. Structures of C5 in complex with the new inhibitors, the phase I and phase II inhibitor OmCI, or an eculizumab Fab reveal three distinct binding sites on C5 that all prevent activation of C5. The positions of the inhibitor-binding sites and the ability of all three C5–inhibitor complexes to competitively inhibit the C5 convertase conflict with earlier steric-inhibition models, thus suggesting that a priming event is needed for activation.
Item Type: | Publication - Article |
---|---|
Digital Object Identifier (DOI): | 10.1038/nsmb.3196 |
UKCEH and CEH Sections/Science Areas: | UKCEH Fellows |
ISSN: | 1545-9993 |
Additional Information. Not used in RCUK Gateway to Research.: | Freely available on PubMed Central(Europe) https://europepmc.org/abstract/MED/27018802 |
Additional Keywords: | electron microscopy, immunology, NMR spectroscopy, proteins, X-ray crystallography |
NORA Subject Terms: | Biology and Microbiology |
Date made live: | 09 Jun 2016 10:20 +0 (UTC) |
URI: | https://nora.nerc.ac.uk/id/eprint/513780 |
Actions (login required)
View Item |
Document Downloads
Downloads for past 30 days
Downloads per month over past year